Inclusion Criteria:  Diagnosis of juvenile psoriatic arthritis (jPsA) by Vancouver criteria with exclusion of enthesitis-related arthritis (ERA). Diagnosis made at least 3 months prior to screening Active disease in at least 3 joints at screening and at week 0 (defined as swelling or loss of motion with pain and/or tenderness Inadequate response (at least 1 month) or intolerance to at least 1 non-steroidal anti-inflammatory drug (NSAID) Inadequate response (at least 3 months) or intolerance to at least 1 nonbiological disease modifying anti-rheumatic drug (DMARD) If using corticosteroids; must be on a stable dose of less than or equal to (<=) 10 milligrams (mg) prednisone equivalent or 0.20 mg per kilograms (kg) per day (whichever is less) for at least 4 weeks before first administration of study intervention. If currently not using corticosteroids, the participant must have not received corticosteroids (intra articular, intramuscular, or intravenous [IV] corticosteroids [including intramuscular corticotropin]) for at least 4 weeks before the first dose administration  Exclusion Criteria:  Participants with ERA Have a history of latent or active granulomatous infection, including tuberculosis (TB), histoplasmosis, or coccidioidomycosis, or have had a nontuberculous mycobacterial infection prior to screening Have a history of, or ongoing, chronic or recurrent infectious disease Has evidence of herpes zoster infection within 8 weeks prior to Week 0 Have a known history of hepatitis C infection or test positive at screening